Rhythm Pharmaceuticals (RYTM) Return on Equity (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Return on Equity data on file, last reported at 0.02% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.02%, up 7.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02% (up 7.0% YoY), and the FY2025 annual result was 0.02%, changed 0.0% from the prior year.
• Return on Equity eased to 0.02% in Q1 2026 per RYTM's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.01% in Q4 2022 and troughed at 0.52% in Q2 2025.
• A 5-year average of 0.06% and a median of 0.01% in 2025 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 14 bps in 2025 and fell as far as 47 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then tumbled by 52 bps to 0.01% in 2023, then plunged by 1473 bps to 0.16% in 2024, then jumped by 91 bps to 0.01% in 2025, then declined by 13 bps to 0.02% in 2026.
• Business Quant data shows RYTM's Return on Equity at 0.02% in Q1 2026, 0.01% in Q4 2025, and 0.03% in Q3 2025.